

KALEIDOSCOPE



May 23<sup>rd</sup>, 2024

ANU - Museum of the Jewish People Tel Aviv University

Round tables May 24<sup>th</sup>, 2024 Port Tower Hotel, Tel Aviv

## STATE OF THE ART AND NEXT QUESTIONS...

## Scientific Program

## THURSDAY, MAY 23<sup>RD</sup> 2024

ANU -	- Museum o	of the Jewis	sh People,	Tel Aviv

08:00-09:00	Registration, Gathering & Exhibition		
09:00-09:20	Opening Remarks Hagop Kantarjian, MD, Chair of the Department of Leukemia, The University of Texas MD Anderson Cancer Center Lena Koren, MD, Director of the Beilinson Campus & Deputy Director of the Rabin Medical Center, Israel Karen Avraham, PhD, Dean of the Faculty of Medicine ₪ Health Sciences, Tel-Aviv University Nati Horowitz, MD, Chairman, Israel Society of Hematology and Blood Transfusions, Israel Gal Markel, MD, Head, Davidoff Cancer Center, Rabin Medical Center, Israel Pia Raanani, MD, Head, Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Israel		
09:20-10:55	Session 1 - Acute Leukemia		
	Chairpersons - Yishai Ofran, <i>MD</i> Galia Stemer, <i>MD</i>		
09:20-09:40	AML 2024: New Classifications, New Targets Richard Stone, MD, Dana Farber Institute, Boston, USA		
09:40-09:55	Incorporation of Targeted and Immune-Based Therapies in Frontline ALL therapy Hagop Kantarjian, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
09:55-10:10	Updates in Post-Remission Maintenance for AML Gail Roboz, MD, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA		
10:10-10:25	Ph +Positive ALL Robin Foa, MD, 'La Sapienza' University of Rome, Italy		
10:25-10:40	An update on venetoclax-based regimens for newly diagnosed AML Courtney DiNardo, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
10:40-10:55	Panel Discussion		
10:55-11:25	Coffee Break & Exhibition		
11:25-12:45	Session 2 - Chronic Lymphocytic Leukemia		
	Chairpersons - Yair Harishanu, MD Nadav Sarid, MD		
11:25-11:45	CLL Therapy: Time-Limited or Continuous Therapy? The Debate Continuous Jan Burger, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
11:45-12:00	Evolving Frontline Therapy of CLL Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
12:00-12:15	CLL 2024: Standards and Open Questions Barbara Eichhorst, MD, University Hospital of Cologne, Germany		
12:15-12:30	Novel Treatments on the Horizon for CLL William (Bill) Wierda, MD, University of Texas MD Anderson Cancer Center, Houston, USA		

12:30-12:40	Panel Discussion		
12:40-13:40	Lunch & Exhibition		
13:40-15:25	Session 3 - Chronic Myeloid Leukemia & Myeloproliferative Disorders		
	Chairpersons: Pia Raanani, MD Ariel Aviv, MD		
13:40-14:00	Treatment Free Remission in CML: Where we Stand? Delphine Rea, MD, Hopital Saint-Louis, Paris, France		
14:00-14:15	Updates on Myeloproliferative Neoplasms Lucia Masarova, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
14:15-14:35	New CML Lab Recommendations for Diagnosis and Monitoring Simona Soverini, PhD, Alma Mater Studiorum Universita di Bologna, Italy		
14:35-14:55	Survival, Causes of Death and Perspectives of TFR in CML Patients: Data from the Italian Campus Registry Giuseppe Saglio, MD, University of Turin, Italy		
14:55-15:10	Re-Assessing Some Established Treatment Practices in CML Hagop Kantarjian, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
15:10-15:25	Panel Discussion		
15:25-15:45	Coffee Break & Exhibition		
15:45-16:05	<ul> <li>Special Debate:</li> <li>CLL - Time Limited Treatment or Treatment Until Progression</li> <li>Moderator: Jennifer Brown, MD, Dana-Farber Cancer Institute (DFCI), Boston, USA</li> <li>Debaters: Tamar Tadmor, MD, Division of Hematology and Blood Bank, Bnai Zion Medical Center, Haifa, Israel &amp; Gilad Itchaki, MD, Hematology, Meir Medical Center, Israel</li> </ul>		
16:05-17:50	Session 4 - Lymphoproliferative Disorders & Plasma Cell Dyscrasias		
	Chairpersons: Ronit Gurion, MD Yael Cohen, MD		
16:05-16:20	Approach to Newly Diagnosed Multiple Myeloma Morie Gertz, MD, Mayo Clinic Rochester Minnesota, USA		
16:20-16:35	Future Directions in Treatment of Hodgkin Lymphoma Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, NY, USA		
16:35-16:50	Divide and Conquer: Evolving Approaches to the Upfront Treatment of Systemic T cell Lymphomas Steve Horwitz, MD, <i>Memorial Sloan Kettering Cancer Center NY, USA</i>		
16:50-17:05	Diagnosing and Treating Plasma Cell Dyscrasias in 2024 Krina Patel, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
17:05-17:20	Updates on Novel Therapies for T cell Lymphoma Swaminathan Padmanabhan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
17:20-17:35	CAR T-Cell Therapy for B-cell Lymphomas, Progress Made and Future Directions Loretta Nastoupil, MD, University of Texas MD Anderson Cancer Center, Houston, USA		
17:35-17:50	Next Questions in Follicular Lymphoma Gilles Salles, MD, Memorial Sloan Kettering Cancer Center NY, USA		
17:50-18:00	Closing Remarks		

## FRIDAY, MAY 24<sup>TH</sup> 2024 Port Tower Hotel, Tel Aviv

09:00-12:00	Round Tables
	Chronic Myeloid Leukemia Delphine Rea, MD; Giuseppe Saglio, MD; Simona Soverini, PhD; Adi Shacham-Abulafia, MD
10:00-11:00	Acute Leukemia Richard Stone, MD; Ofir Wolach, MD
	Short Break
11:00-12:00	Chronic Lymphocytic Leukemia Jan Burger, MD; Tamar Tadmor, MD; Gilad Itchaki, MD; Barbara Eichhorst, MD